Table 2 Study outcomes
From: Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial
Outcome | Total N = 229 | CLARITHRO n = 6127% | CIPRO n = 5624% | METRO n = 5725% | CIPRO-Plus n = 5524% | p-value1 | |
|---|---|---|---|---|---|---|---|
Treatment failure (Positive FAT) (%) | Total group (n = 85) | 20 | 13 | 18 | 36 | 12 | 0.191 |
No prior exposure to triple therapy (n = 73) | 22 | 14 | 21 | 39 | 14 | 0.265 | |
HRQoLin total group (mean ± SD) | Score after treatment | 32 ± 11 | 31 ± 10 | 31 ± 10 | 36 ± 12** | 31 ± 9 | 0.023 |
Mean difference | 44 ± 14 | 46 ± 15 | 44 ± 15 | 40 ± 13* | 47 ± 13 | 0.032 | |
HRQoL in functional dyspepsia (n = 37) (mean ± SD) | Score after treatment | 30 ± 9 | 33 ± 13 | 28 ± 7 | 32 ± 6 | 24 ± 5 | 0.229 |
Mean difference | 42 ± 15 | 38 ± 17 | 42 ± 17 | 42 ± 10 | 51 ± 16 | 0.392 | |
Persistence of symptoms (%) | Total group (n = 229) | 22 | 18 | 23 | 26 | 20 | 0.715 |
No prior exposure to triple therapy (n = 189) | 23 | 19 | 26 | 29 | 18 | 0.492 | |